Sponsor: Napo Pharmaceuticals
Protocol NP303-102: A Phase 3 multicenter, randomized, double-blind placebo-controlled trial evaluating crofelemer for the prophylaxis of diarrhea in adult patients with solid tumors receiving targeted-cancer therapies with or without standard chemotherapy regimens
Crofelemer for diarrhea prophylaxis in patients with a solid tumor starting treatment with a targeted therapy with a reported incidence of diarrhea of at least 50%.
Eligible targeted therapies include (but are not limited to): abemaciclib, afatinib, axinitib, alpelisib, brigatinib, cabozantinib, ceritinib, cobimetinib, crizotinib, dacomitinib, erlotinib, gefitinib, lapatinib, lenvatinib, osimertinib, pazopanib, pertuzumab, sorafenib, sunitinib, tucatinib, and vandetanib
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly at 631-675-5075.